Protective effect of systemic administration of pravastatin against noise-induced hearing loss in the Fischer 344/NHsd rat substrain by Sanders, Jennifer Morgan
PROTECTIVE EFFECT OF SYSTEMIC ADMINISTRATION 
OF PRAVASTATIN AGAINST NOISE-INDUCED HEARING LOSS 
IN THE FISCHER 344/NHsd RAT SUBSTRAIN 
 
 
Capstone Project 
 
 
Presented in Partial Fulfillment of the Requirements for 
 
the Doctor of Audiology  
 
in the Graduate School of The Ohio State University 
 
 
 
By 
 
 
JENNIFER MORGAN SANDERS, B.S. 
 
***** 
 
 
The Ohio State University 
2012 
 
 
 
 
Capstone Committee:     Approved by 
 
ERIC C. BIELEFELD, Ph.D., Advisor                
 
LAWRENCE L. FETH, Ph.D. 
 
GAIL M. WHITELAW, Ph.D. 
 
______________________________ 
 Advisor 
  
© Copyright by 
Jennifer Morgan Sanders, B.S. 
2012 
 ii 
ABSTRACT 
 
The deleterious effects of noise-induced hearing loss (NIHL) on the auditory 
system have been well documented, contributing to temporary thresholds shifts (TTS) 
and permanent threshold shifts (PTS). The generation of reactive oxygen species (ROS) 
greatly contributes to the pathogenesis of NIHL, and as such is a target for 
pharmacological intervention by strengthening the antioxidant defense system in the 
body.  
Previous studies suggest that pravastatin may lower ROS production and block 
apoptotic cell death. As such, the aim of this study was to examine the protective effect of 
pravastatin against noise in the Fischer 344/NHsd rat substrain. The noise condition was a 
2-octave band continuous noise of 4 kHz – 16 kHz, delivered at 110 dB SPL combined 
with 120 dB pSPL impacts. In the treated group, pravastatin was administered via 
intraperitoneal injections (12 mg/kg) 24 hours before noise exposure; 1 hour prior to and 
1 hour following noise exposure; and then 24 hours post noise exposure.  
Threshold shifts for the treated versus untreated groups were assessed at 6 
frequencies (5, 10, 15, 20, 30, and 40 kHz) and were obtained 1 day and 14 days after the 
noise to document TTS and 28 days post noise to document PTS. The 3-way ANOVA 
did not show a significant main effect (p < .05) of Group or Frequency, nor any 
significant interaction involving treatment groups. There was a trend toward significance 
for the interaction of Day and Group (p = 0.057). Recovery functions indicated that, from 
Day 14 to Day 28, the treated group demonstrated a decrease in thresholds that the 
untreated control group did not. While this study did not indicate a significant protective 
 iii 
effect of pravastatin, further investigation of pravastatin’s protective capacity against 
NIHL is needed to extrapolate therapeutic strategies caused by ROS overproduction. 
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                                     CHAPTER 1 
Introduction 
 The adverse effects of ambient noise and chronic noise exposure on the auditory 
system have been well documented. One-third of persons with hearing impairment 
partially attribute their loss to noise exposure, mainly occupational noise exposure (NIH, 
1990). In an industrial environment, exposure to 85 – 90 dB(A) noise levels can lead to 
hearing loss (HL). Additionally, noise exposure may adversely affect one’s health and 
quality of life, which implies that noise exposure is a significant public health concern in 
industrialized nations (Passchier-Vermeer & Passchier, 2000). In addition to its effects on 
hearing, noise may be perceived as an environmental stressor that impacts one’s general 
health and cognitive processes (Stansfeld & Matheson, 2003). Literature regarding the 
non-auditory effects of noise centers on the psychological and physiological effects of 
noise exposure, namely communication interference, sleep interference, cognitive 
performance, and cardiovascular and neuroendocrine factors.  
1.1. Cochlear mechanics 
In a typically developing person, the peripheral auditory system consists of an 
outer ear (OE), middle ear (ME), and an inner ear (IE). Each portion influences 
transmission of acoustic stimuli. The process of sound transmission is initiated when an 
acoustic stimulus enters the auditory system via the OE, which is comprised of the pinna 
and the external auditory meatus (EAM). The acoustic stimulus then traverses through 
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the EAM to the ME; the EAM directs acoustic signals to the tympanic membrane. The 
resonance properties of the EAM lead to amplification of sounds in the 1.5 kHz – 7 kHz 
range. The ME space, or tympanic cavity, consists of the tympanic membrane, ossicular 
chain (i.e., malleus, incus, and stapes), and the Eustachian tube. Additionally, structures 
housed within the tympanic cavity consist of tendons from 2 ME muscles (i.e., tensor 
tympani and stapedius). The primary function of the ME is to serve as an impedance 
matching element between the air-filled ME and the fluid-filled IE. After passing through 
the OE and ME, the acoustic stimulus is delivered to the cochlea. As part of the sound 
transmission process, the OE and ME are responsible for conducting sound energy and 
increasing sound intensity. The acoustic stimulus is converted from acoustic energy to 
electrochemical energy at the level of the cochlea. It is then the responsibility of the 
auditory nerve to transmit the electrochemical impulses centrally. 
 The cochlea has several thousand hair cells (HC) and nerve endings (afferent and 
efferent nerve fibers). The organ of Corti is the sensory organ in the IE that contains the 2 
types of HC: 1) outer HC (OHC) and 2) inner HC (IHC) (Musiek & Baran, 2007b). Both 
types of HC form synapses with the nerve fibers, which allows communication with the 
nerve fibers. The majority of efferent nerve fibers innervate OHC. In contrast, the 
majority (~85 – 95%) of afferent nerve fibers innervate IHC. On the apical end of each 
HC are stereocilia, which respond to fluid motion from an acoustic stimulus (Musiek & 
Baran, 2007a). The deflection of stereocilia leads to an action potential in a process called 
depolarization. Conversely, hyperpolarization inhibits the onset of an action potential. 
Both depolarization and hyperpolarization must occur for the active mechanism to 
transduce sound effectively. The cochlea is organized to enable HC transduction. Insult to 
 3 
 
the cochlea has the potential to cause the stereocilia to become flaccid or fuse the 
stereocilia together, thus not permitting the depolarization process to occur (Musiek & 
Baran, 2007a). The HC transduction process commences when an acoustic stimulus 
evokes vibrations of the cochlear partition that are then converted into electrical activity. 
On OHC and IHC, the mechanically gated transduction channels are located near the tip 
of the stereocilia; the transduction channels are responsible for converting sound into 
neural activity. The stereocilia deflect toward the tallest stereocilia, thereby increasing the 
number of open transduction channels, resulting in the depolarization process (Musiek & 
Baran, 2007a). Conversely, deflection towards the shortest stereocilia increases the 
number of closed transduction channels, resulting in hyperpolarization of a given HC. 
When channels are open, positive potassium (K+) ions in the endolymph flow into the 
HC. The active HC transduction mechanism facilitates communication between the HC 
and the nerve fibers (Musiek & Baran, 2007a). An IHC action potential leads to release 
of excitatory neurotransmitter into the synaptic cleft with the afferent auditory nerve 
fibers terminals. The afferent auditory pathway (IHC transduction) transmits information 
to the central auditory nervous system (CANS). The efferent auditory pathway, or 
descending pathway, transmits information from the central levels of the auditory system 
to the peripheral levels of the auditory system. Both afferent and efferent pathways must 
be functioning in order for a person to optimally perceive sounds in the variety of 
listening environments.  
1.2. Pathogenesis of NIHL 
Noise-induced cell death may occur by various complex mechanisms. As a result 
of acoustic trauma exposures, active mechanisms at the cellular level trigger HC death. 
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Noise exposure increases levels of ROS during and after the noise exposure (Henderson, 
Bielefeld, Harris, & Hu, 2006). ROS include oxygen-based free radicals, chemical 
species with an unpaired electron, thus capable of altering electron arrangements in stable 
molecules. ROS break down cell membranes through lipid peroxidation, leading to cell 
death. The expression ‘oxidative stress’ describes numerous detrimental processes due to 
an imbalance between excessive formation of ROS and the significant decrease in the 
effectiveness of antioxidant defenses. In addition, genetic factors and aging may cause an 
increased concentration of ROS. A buildup of ROS in cells will cause damage to nucleic 
acids, lipid membranes, and proteins, thereby disrupting normal cellular functions. 
 The biological processes of cell death after noise exposure include necrotic and 
apoptotic cell death. Necrosis is acquired cell death, or a passive form of cell death, that 
is due to physical or chemical insults. Cell swelling results; in so doing, this leads to 
rupture of the cell and a subsequent releasing of its contents into the extracellular spaces. 
Because the cell disassembles, the ability to regulate the intracellular environment has 
been lost. This process evokes an inflammatory response and causes irreversible damage 
to surrounding tissue.  
Necrosis was thought to be the primary mode of cell death in the noise-exposed 
cochlea. However, the existence of apoptosis, or programmed cell death, has also been 
observed in the noise-damaged cochlea (Hu, Guo, Wang, Henderson, & Jiang, 2000; Hu, 
Henderson, & Nicotera, 2002). Apoptosis is a necessary part of nervous system 
development in all animals. Unlike cell death due to injury, apoptotic cell death is 
required for proper development and morphogenesis (Henderson et al., 2006). 
Furthermore, programmed cell death is needed to destroy cells that represent a threat to 
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the integrity of multicellular organisms, such cells with viral infection, cells in states of 
extreme stress, cells with DNA damage, and cancer cells. Apoptosis is a regulated 
process, conducted in a predictable and reproducible pattern, which requires energy 
expenditure (Henderson et al., 2006). The cell membrane remains intact, and the cell 
pulls away from bordering cells. Morphologic cellular changes include the following: 
blebbing, cell shrinkage, nuclear fragmentation, chromatin condensation, and DNA 
fragmentation. During apoptosis, inflammation does not occur since cellular contents are 
not released. The noise-induced lesion of dead OHC results from a combination of 
apoptosis and necrosis. However, the OHC lesion grows primarily via apoptosis, and the 
lesion grows toward the basal side of the cochlea (Hu et al., 2002).  
Several different forms of cellular damage occur, because noise abuses the 
cochlea metabolically and mechanically. Also, HC dying for several days or weeks after 
an exposure presents two questions: 1) Can HC be protected, thus preventing subsequent 
cochlear damage and HL, by neutralizing ROS as they are formed? 2) Can researchers 
limit HC loss via pharmacological intervention that inhibits the disassembly of the HC 
through apoptosis? 
1.3. Current intervention strategies 
Noise-induced HL (NIHL), due to acute or chronic noise trauma, depends on the 
frequency content, sound pressure level, exposure time, in addition to an individual’s 
susceptibility to noise. NIHL may cause substantial communication difficulties, which 
can be partially managed by the utilization of hearing aids, assistive listening technology, 
and aural rehabilitative measures. In general, HL is currently managed by device-related 
modalities, which may generate reasonable results for some individuals. These 
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rehabilitation strategies may improve the quality of life for individuals with NIHL; 
however, it is important to note that technology does not restore natural hearing nor does 
it replace the processing capabilities of a normal auditory system.  
HC regeneration, currently, is not an option for reversing the effects of NIHL. 
Also, there are no drugs that have been approved by the Food and Drug Administration 
(FDA) for the prevention or treatment of NIHL. Consequently, there is a need for 
researchers to uncover alternative therapies to protect against or lessen the effects of 
NIHL. There is a search for otoprotective agents or pharmacological interventions that 
could potentially protect cochlear HC from excessive noise exposure, or lessen its 
harmful effects. Augmentation of the antioxidant defense system is an objective for 
pharmacological prevention. In terms of intervention strategies, there are 2 schools of 
thought, one being ‘protection’ (i.e., providing the drug treatment before the noise 
exposure) and the other being ‘rescue’ (i.e., providing the drug treatment after the noise 
exposure). It is important to note that though some otoprotective agents have shown 
protection against NIHL in animal studies, the agents may pose safety issues for humans 
if administered systematically. 
As previously discussed, an increase in ROS, byproducts of mitochondrial 
respiration, plays a significant role in the exacerbation of NIHL. Therefore, it is thought 
that increasing antioxidant activity may counteract ROS formation, or apoptotic 
intracellular signaling process may be impeded in order to promote cell survival.  
There is evidence that antioxidants may be beneficial when treating or preventing the 
onset or progression of NIHL. Antioxidant vitamins scavenge free radicals. Additionally, 
they prevent oxidative damage from spreading by interrupting lipid peroxidation. Many 
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otoprotective agents are micronutrients that occur in one’s typical daily diet, such as 
vitamins A, C, and E, and magnesium (Le Prell, Hughes, & Miller, 2007). The mineral 
magnesium activates enzymes, contributes to protein synthesis and energy production, 
and assists in regulating calcium levels, when in combination with copper, zinc, 
potassium, and vitamin D. Magnesium preserves blood flow to the IE and aids in healing 
the cells. Furthermore, resveratrol, a nutritional supplement found in the skin of red 
grapes and an active component in red wine, may provide some protection against NIHL. 
A study by Seidman, Babu, Tang, Naem, and Quirk (2003) demonstrates a protective 
effect of resveratrol on NIHL, in which the resveratrol group showed reduced threshold 
shifts after a 7 week resveratrol treatment. 
 Acety-L-carnitine (ALCAR) and n-l-acetyl cysteine (LNAC) have also been 
shown to play a significant role in ameliorating the effects of NIHL. ALCAR is a 
molecule that aids in maintaining mitochondrial efficiency. LNAC promotes cell 
detoxification and increases levels of the antioxidant glutathione, which neutralizes the 
toxic hydroxyl radical and peroxynitrite. D-Methionine may also increase glutathione 
levels within the cell. Both ALCAR and LNAC are antioxidants that may protect the 
cochlea from impulse noise (Kopke et al., 2005). To illustrate, in a study by Kopke et al. 
(2005), chinchillas received ALCAR or LNAC as a pre- and post-treatment to lessen the 
effects of impulse noise. Results revealed that PTS were roughly 10 – 30 dB less than the 
control group 3 weeks after noise exposure. 
1.4. Pravastatin 
As reviewed above, numerous pharmacological strategies to attenuate NIHL have 
been tested in animal models. Acoustic trauma generates ROS in the pathogenesis of 
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NIHL, and as such is a focus for pharmacological intervention by strengthening the 
antioxidant defense system in the body. HMG-CoA reductase inhibitors (statins) are a 
class of prescription drugs to reduce blood levels of LDL cholesterol and preventing 
cardiovascular disease. Pravastatin is a lipo-protein lowering drug. The drug works by 
inhibiting the function of HMG-CoA reductase by occupying the site of the enzyme. This 
process takes place primarily in the liver, thus slowing the production of cholesterol in 
the body. Atherosclerosis, or hardening of the arteries, occurs when fat, cholesterol, and 
other substances build up in the walls of arteries and form plaques. This causes a decrease 
in blood flow, thereby the O2 supply to the heart, brain, and other parts of the body. 
Lowering blood levels of cholesterol and other fats may help to decrease an individual’s 
chances of receiving a myocardial infarction. Pravastatin also works to enhance the 
antioxidant defense system and inhibit apoptosis, which along with possible 
improvements in blood circulation make pravastatin a potential therapeutic agent to 
protect against NIHL.          
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CHAPTER 2 
Materials and Methods 
A total of 6 male and 6 female Fischer 344/NHsd rats were used in the study. 
They were obtained from Harlan Laboratories at age 2 – 3 months. The animals were 
housed in The Ohio State University Laboratory Animal Resources colony adjacent to the 
laboratory in which the experiment was conducted. The animals were divided into 1 
experimental group and 1 control group (3 males and 3 females in each group). The noise 
levels did not exceed 60 dB (Leq) over any 24-hour period in the housing facility. 
Ambient sound levels were monitored with a sound level meter (Larson Davis LxT1 and 
ACO ½ inch condenser microphone). All procedures involving use and care of the 
animals were reviewed and approved by The Ohio State University Institutional Animal 
Care and Use Committee. 
2.1. Pravastatin treatment  
 Pravastatin was dissolved in distilled water at a concentration of 1.56 mg/ml. To 
investigate protective effects, 4 injections were administered: 24 hours before noise 
exposure; 1 hour prior to and 1 hour following noise exposure; and then 24 hours post 
noise exposure. For each animal, a dose of 12 mg/kg was delivered in each 
intraperitoneal injection, for a total volume of ~2 ml per injection. Equivalent volumes of 
distilled water were administered to the control group. 
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2.2. Evoked potential testing 
Hearing thresholds were obtained by recording free-field auditory brainstem 
response (ABR). For all ABR test procedures, the animals were anesthetized with 
inhalant isoflurane (4% for induction, 1.5% for maintenance, 1 L/min O2 flow rate). 
Needle recording electrodes were placed at the vertex (non-inverting), below the left 
pinna (inverting), and below the right pinna (ground). For threshold testing, test stimuli 
consisted of alternating phase tone bursts at frequencies 5, 10, 15, 20, 30, and 40 kHz. All 
stimuli were generated using Tucker Davis Technologies (TDT, Gainesville, FL) SigGen 
software. Each tone burst was 1 ms in duration, and had a 0.5 ms rise/fall time with no 
plateau. Each tone burst was gated through a Blackmann window, and presented at a rate 
of 21/sec. Signals were routed to a speaker (TDT Model MF1) positioned at zero degrees 
azimuth, 17 cm from the vertex of each rat’s head. Acoustic stimuli were calibrated prior 
to each testing session by recording the output of the speaker with a microphone placed at 
the animals’ head level. The rats’ evoked responses were amplified with a gain of 50,000, 
using a TDT RA4LI headstage connected to an RA4PA pre-amplifier, and bandpass 
filtered from 100 – 3000 Hz. 250 sweeps were averaged at each stimulus level using TDT 
BioSig software. The level of the signal was decreased in 5 dB steps from 90 dB SPL 
until threshold was reached. Threshold was defined as the lowest level at which a 
detectable response was elicited.  
2.3. Noise exposure 
 Each animal was exposed to a noise exposure condition. The noise was a 2-octave 
band continuous noise of 4 kHz – 16 kHz, delivered at 110 dB SPL combined with 120 
dB pSPL impacts. The rate of impacts was 1/sec. The duration of the combined 
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continuous and impact noise was 120 minutes. The noise was created on TDT RPvdsEX 
visual design software and then generated using a TDT RP2 Real time signal processor, 
amplified by a Marathon DJ-5000 power amplifier (New York, NY). The noise signal 
was then delivered to a speaker (Vifa D25AG35 1” Dome Tweeter, Madisound Speaker 
Components, Inc., Middleton, WI) mounted on the side of a wire cage in which the 
animals were held for the noise exposure. The noise level was calibrated at the level of 
the animals’ head utilizing a LxT1 sound level meter (Larson Davis Inc., Depew, New 
York) and a 1/2’’ condenser microphone. Food and water were available throughout the 
duration of the noise exposures. 
2.4. Assessment of threshold shift 
Threshold shifts were calculated by subtracting pre-exposure thresholds from 
those obtained 24 hours and 14 days post noise exposure to investigate TTS and 28 days 
post noise exposure to investigate PTS. 
2.5. Statistical analysis 
 A 2-factor ANOVA (Group x Frequency) was used to test pre-exposure 
thresholds between the 2 groups, and a 3-factor ANOVA (Group x Frequency x Day) was 
used to analyze differences between the mean ABR thresholds of the 2 groups across the 
6 different test frequencies (5, 10, 15, 20, 30, and 40 kHz) pre- and post-noise exposure. 
  
 12 
 
 
 
 
CHAPTER 3 
RESULTS 
Mean pre-noise exposure thresholds are displayed in Figure 1. The 2-way 
ANOVA did not show a significant main effect (p < .05) of group, but did reveal a 
significant main effect of frequency (p < 0.01).  The main effect of frequency was 
expected due to the higher mean thresholds at 30 kHz and 40 kHz, compared with the 
lower frequencies 5 kHz – 15 kHz.  The lack of effect of group indicated that the rats in 
the pravastatin group had hearing that was equally sensitive as the rats in the control 
group.   
Threshold shifts for the 2 groups at the 6 frequencies are shown for Day 1 (Figure 
2) and Day 14 (Figure 3) to document TTS and Day 28 (Figure 4) to document PTS. 
Generally, across the frequencies, the 3-way ANOVA also did not show a significant 
main effect (p < .05) of Group, Frequency, and Day, nor any significant interaction 
involving groups. There was a trend toward a significant interaction of Day and Group  
(p = 0.057), suggesting that with larger sample sizes, a significant interaction might have 
been found.  From Day 1 – 14, a threshold shift recovery was documented. From Day 14 
– 28, a flat HL was skewed across the low frequencies, and then an increase in thresholds 
was noted at 30 kHz and 40 kHz, indicating threshold shift recovery. 
For further clarification of the data, plots were created that show recovery 
functions from Day 1 to Day 28 at each of the tested frequencies: 5 kHz (Figure 5), 10 
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kHz (Figure 6), 15 kHz (Figure 7), 20 kHz (Figure 8), 30 kHz (Figure 9), and 40 kHz 
(Figure 10). Largely, the recovery functions indicate that, from Day 14 to Day 28, the 
treated group demonstrated a decrease in thresholds while the untreated group’s 
thresholds actually increased.   
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Figure 1. Mean pre-noise exposure thresholds for the treated and 
untreated groups. 
Figure 1 
Pre-Noise Exposure Thresholds 
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Figure 2. Day 1 noise exposure threshold shift for the treated and 
untreated groups. 
Figure 2 
Day 1: Noise Exposure Threshold Shift 
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Figure 3. Day 14 noise exposure threshold shift for the treated and 
untreated groups. 
Figure 3 
Day 14: Noise Exposure Threshold Shift 
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Figure 4. Day 28 noise exposure threshold shift for the treated and 
untreated groups. 
Figure 4 
Day 28: Noise Exposure Threshold Shift 
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Figure 5. Day 1 - Day 28 threshold recovery function (5 kHz) for the 
treated and untreated groups. 
Figure 5 
5 kHz: Treated Group vs. Untreated Group Across Days 
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Figure 6. Day 1 - Day 28 threshold recovery function (10 kHz) for the 
treated and untreated groups. 
Figure 6 
10 kHz: Treated Group vs. Untreated Group Across Days 
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Figure 7. Day 1 - Day 28 threshold recovery function (15 kHz) for the 
treated and untreated groups. 
Figure 7 
15 kHz: Treated Group vs. Untreated Group Across Days 
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Figure 8. Day 1 - Day 28 threshold recovery function (20 kHz) for the 
treated and untreated groups. 
Figure 8 
20 kHz: Treated Group vs. Untreated Group Across Days 
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Figure 9. Day 1 - Day 28 threshold recovery function (30 kHz) for the 
treated and untreated groups. 
Figure 9 
30 kHz: Treated Group vs. Untreated Group Across Days 
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Figure 10. Day 1 - Day 28 threshold recovery function (40 kHz) for the 
treated and untreated groups. 
Figure 10 
40 kHz: Treated Group vs. Untreated Group Across Days 
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CHAPTER 4 
Discussion 
The role of pharmacological agents in the management of NIHL continues to be 
expanded. This study did not show a statistically significant protective effect of 
pravastatin, a rate-limiting enzyme of cholesterol synthesis, in Fischer 344/NHsd rats. 
Since the time this study was conducted, pravastatin has been shown to have a protective 
effect against cochlear injury in mice. In a study administered by Park et al. (2012), 
pravastatin reduced HC death in the cochlea after noise exposure and decreased threshold 
shifts as well. Furthermore, noise-induced increases in 4-HNE, which is a byproduct of 
lipid peroxidation in the cell membrane, were found to be reduced by pravastatin 
treatment. Additionally, Rac1, a subunit of the NADPH oxidase complex, was inhibited 
by the administration of pravastatin. The NADPH oxidase complex is a superoxide 
generator. The study suggests pravastatin may protect the cochlea against NIHL by 
lowering ROS overproduction. 
What remains unclear is why the current study was unsuccessful in protecting 
against NIHL. The possibility exists that the sample sizes of 6 rats per group was too low 
to see a significant effect, since there was a statistical trend for a Group x Day interaction.  
That interaction is not clearly showing protection, since the control group showed lower 
mean threshold shifts at Day 14 than the treated group. Though, on Day 28, the treated 
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animals had lower threshold shifts than the controls. Expanding the study to include more 
animals would likely help make the nature of an interactive effect clearer.  
Also, in the Park et al. (2012) study, BALB/c mice were utilized, which may have 
contributed to the positive outcome of the study. Mice animal models are the 
predominant model for hearing research, primarily with regards to age-related HL 
(ARHL) and NIHL studies (Ohlemiller, 2006). There are numerous reasons that have 
contributed to the growth in the application of mice in auditory research. The effects of 
noise in mouse cochleae have been studied more extensively than in the Fischer 
344/NHsd rat. Mouse studies have revealed peripheral pathology in addition to 
transneuronal effect of noise trauma. Practical advantages of utilizing mice include their 
short life span; therefore, the effects of noise (and age) are apparent in a shorter 
timeframe. According to Zheng, Johnson, and Erway (1999), many inbred strains of mice 
exhibit a degree of delayed, progressive hearing loss, which is beneficial in reviewing 
mice model findings and integrating such findings within the contextual basis of NIHL. 
Additionally, there is an ease of genetic standardization and genetic engineering 
(Ohlemiller, 2006). The mouse genome can be applied to humans since mice have a 
genetic similarity to humans in addition to minimal variance within strains. Mice are 
vulnerable to noise; in fact, across inbred strains, there is widespread discrepancy in noise 
vulnerability, which can be particularly useful for studies of NIHL. There are genetic 
influences on noise susceptibility. Mouse genes and alleles may promote NIHL 
(Ohlemiller, 2006). To demonstrate, B6 mice follow autosomal recessive inheritance 
(Erway, Shiau, Davis, & Kreig, 1996). These mice demonstrate a progressive loss of HC, 
with a degeneration of afferent neurons, stria vascularis, and spiral ligament.  
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Mouse cochleae are short in length, thus allowing for fewer basal-apical sampling 
points in studies designed to quantitatively assess HC and neuronal counts in the organ of 
Corti, spiral ligament and spiral limbus, and the stria vascularis in addition to 
classification of afferent synapses (Ohlemiller, 2006). Acoustic injury to 1 cell type may 
aggravate injury to other cell types. It is important to note that it may be challenging to 
provide a direct comparison between mice and human hearing sensitivity, in terms of 
determining which cochlear regions are adversely affected, since mouse and human 
hearing overlap over roughly 3 octaves (~2.5 kHz – 20 kHz) (Ohlemiller, 2006). 
Additionally, in certain strains of mice, the major form of the melanin pigment, 
eumalanin, may protect the cochlear lateral wall by providing antioxidant effects 
(Barrenas, 1997). Oxidative stress may be exacerbated by the melanin isoform, 
pheomelanin. Eumalanin has a role in protecting cochlear HC from noise trauma. 
Moreover, minimal reduction in endocochlear potential (EP), as well as corresponding 
anatomical correlates of EP, was demonstrated post noise exposure.  
There is an interactive effect between age and noise. Mice models provide 
evidence of windows of increased susceptibility to noise exposure. A period of 
heightened vulnerability is from adolescence into early adulthood, which is up to 
approximately 4 months of age in mice. In the Park et al. (2012) study, the mice were 7 – 
8 weeks old. In the current study, the rats were 2 – 3 months old. This suggests that the 
age of the animals should not have contributed to the susceptibility of the noise exposure. 
Overall, mouse models may be more susceptible to NIHL. If a group of animals is more 
susceptible to noise trauma, then pravastatin may provide a greater protective effect 
against NIHL in those animals.  
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Different doses and varying time schedules of administration need to be tested in 
subsequent studies to determine whether a statistically significant protective benefit of 
pravastatin against NIHL can be achieved in rat animal models. To illustrate, in the study 
administered by Park et al. (2012), the BALB/c mice received a pre-treatment with 
pravastatin (25 mg/kg) for 5 days prior to noise exposure. In the current study, 4 
injections were administered (12 mg/kg) in Fischer 344/NHsd rats: 24 hours before noise 
exposure; 1 hour prior to and 1 hour following noise exposure; and then 24 hours post 
exposure. Therefore, the total amount of pravastatin delivered in the Park et al. (2012) 
study was substantially greater than the amount given in the current study. Pre-treating 
with higher doses over a long period of time before the noise could easily create a more 
successful protection effect.   
To further explain the discrepancy between the current study and the Park et al., 
(2012) study, one must consider the type of noise. In the Park et al. (2012) study, animals 
were exposed to a 112 dB SPL broadband white noise (1 kHz – 20 kHz) for 3 hours. In 
the current study, as previously mentioned, the noise was a 2-octave band continuous 
noise of 4 kHz – 16 kHz. The noise was delivered at 110 dB SPL combined with 120 dB 
pSPL impacts, and the rate of impacts was 1 per second. The duration of the combined 
continuous and impact noise was 120 minutes. A chief difference between the current 
study and the study conducted by Park et al. (2012) is the utilization of impact noise. 
Noise damage negatively affects cellular subsystems of the IE. Impact sounds, such as 
gunfire, are particularly menacing to the cochlea since it may lead to immediate 
mechanical damage that cannot be prevented pharmacologically. The impact noise in this 
study may have caused greater damage than a cochlea not otherwise exposed to impact 
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noise. This suggests that the impact noise may have prevented the pravastatin from 
providing optimal protective assistance.  
Furthermore, the mice in the Park et al. (2012) study were examined immediately 
and within 24 hours post noise exposure in addition to 14 days after noise exposure to 
evaluate PTS. In this study, the rats were examined 1 hour before, 1 hour after, and 24 
hours post noise exposure, similar to the Park et al. (2012) study. However, the rats were 
evaluated 28 days post noise exposure to evaluate PTS in this study. Evaluating the 
animals over a greater time period will more than likely be valuable in determining over 
what days, if at all, the greatest amount of threshold shift recovery occurs.  
In addition to the type of noise used, researchers much consider how the method 
of administering the drug may affect the protective capacity of pravastatin. In the current 
study, a dose of 12 mg/kg was delivered in each intraperitoneal injection. In the Park et 
al. (2012) study, the mice were pre-treated with 25 mg/kg of pravastatin orally via 
gavage. Because of this method of administration, and since a greater dosage of 
pravastatin was utilized, Park and his colleagues were possibly able to introduce more 
drug into the cochleae. However, because the exact amount of the drug that reaches the 
cochleae is not known, it is difficult to regulate dosages and time schedules of 
administration. 
The potential mechanisms of action of pravastatin in the cochlea are still unclear.  
The relationship between cholesterol and auditory function has been previously reviewed. 
According to Levic and Yamoah (2011), HC development and OHC tuning is in part due 
to membrane cholesterol. However, high triglyceride levels and plasma cholesterol may 
augment the development of HL due to acoustic overstimulation. This may be due to 
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increased blood viscosity and atherosclerosis (Sutbas et al., 2007). Moreover, HC may 
demonstrate a larger uptake of cholesterol due to an increased stiffness in the IE, thus 
promoting a greater degree of hearing loss. Statins are thought to lessen the inflammatory 
responses of the IE as well as provide vascular protective effects by regulating ROS 
levels (Ohlemiller, 2006). Ischemia injury from the stria vascularis is an underlying 
mechanism for NIHL, and as such statins affect the stria vascularis, thereby attenuating 
the effects of NIHL via the inhibition of the NADPH oxidase complex formation (Park et 
al., 2012).  
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CHAPTER 5 
Conclusion 
NIHL is a leading occupational disease and contributes to the development and 
progression of ARHL (Lynch & Kil, 2005). It is known that acoustic trauma can lead to a 
physical disruption of the organ of Corti along with necrosis and apoptosis at the 
molecular level. Consequently, for the past 20 years, the pharmacological prevention and 
treatment of NIHL has been investigated (Lynch & Kil, 2005). In humans, a lack of 
noise-related cochlear injury studies have been observed due to incomplete noise 
histories and since most temporal bones examined demonstrate mixed pathology 
(Ohlemiller, 2006). Randomized, double-blinded, placebo controlled studies in humans is 
needed to investigate the effects of pravastatin in humans, eventually leading to the 
development of clinical application. Drugs that successfully prevent or treat NIHL will 
more than likely have a substantial impact on one’s overall quality of life, including 
medical costs and disability compensation (Lynch & Kil, 2005). Currently, otoprotective 
agents have not received FDA approval for clinical use. In the foreseeable future, 
audiologists will be working with patients and physicians, either for clinical applications 
or research purposes, in selecting and monitoring pharmacological otoprotective agents 
against NIHL. 
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